Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Next Previous
Search
Trial Profile

A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Eosinophilic gastroenteritis
  • Focus Therapeutic Use
  • Acronyms ENGAGE
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 26 Feb 2024 Trial design presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 13 Nov 2023 Trial design presented at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
  • 12 May 2023 Planned End Date changed from 21 Jul 2027 to 19 Aug 2027.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top